Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.073,04
-0,14%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Pharming Group NV (PHARM) Pharming Group NV (PHARM) Notizie

PHARM

Pharming Group NV (PHARM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:PHARM
DataOraFonteTitoloSimboloCompagnia
15/12/202419:45GlobeNewswire Inc.Pharming announces public cash offer to the shareholders of Abliva ABEU:PHARMPharming Group NV
11/12/202407:00GlobeNewswire Inc.Pharming announces positive topline data in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
05/11/202408:00GlobeNewswire Inc.Pharming Group to participate in November investor conferenceEU:PHARMPharming Group NV
24/10/202407:00GlobeNewswire Inc.Pharming Group reports third quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
10/10/202408:00GlobeNewswire Inc.Pharming Group to report third quarter 2024 financial results on October 24EU:PHARMPharming Group NV
10/10/202407:00GlobeNewswire Inc.Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulationEU:PHARMPharming Group NV
26/09/202407:00GlobeNewswire Inc.Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)EU:PHARMPharming Group NV
04/09/202407:00GlobeNewswire Inc.Pharming Group to participate in September investor conferencesEU:PHARMPharming Group NV
01/08/202407:00GlobeNewswire Inc.Pharming Group reports second quarter and first half 2024 financial results and provides business updateEU:PHARMPharming Group NV
18/07/202408:00GlobeNewswire Inc.Pharming Group to report second quarter and first half 2024 financial results on August 1EU:PHARMPharming Group NV
03/06/202408:00GlobeNewswire Inc.Pharming Group to participate in June investor conferencesEU:PHARMPharming Group NV
30/05/202422:44GlobeNewswire Inc.Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European UnionEU:PHARMPharming Group NV
21/05/202417:30GlobeNewswire Inc.Pharming Group reports on results of the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
20/05/202408:00GlobeNewswire Inc.Pharming Group to participate in May investor conferenceEU:PHARMPharming Group NV
15/05/202407:00GlobeNewswire Inc.Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/05/202407:00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202408:00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202407:00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202418:43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202415:04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202408:00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202407:00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202408:30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202407:00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202408:00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202407:00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202408:00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202408:00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202407:00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202307:00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:PHARM

La tua Cronologia

BIT
F15922
Vontobel Financial Produ...
BIT
UC6Y5K
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network